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Abstract
Critical care physicians often find themselves prognosticating for
their patients, attempting to predict patient survival as well as
disability. In the case of neurologic injury, this can be especially
difficult. A frequent cause of coma in the intensive care unit is
resuscitation following cardiac arrest, for which mortality and
severe neurologic disability remain high. Recent studies of the
clinical examination, of serum markers such as neuron-specific
enolase, and of somatosensory evoked potentials allow accurate
and specific prediction of which comatose patients are likely to
suffer a poor outcome. Using these tools, practitioners can
confidently educate the family for the majority of patients who will
die or remain comatose at 1 month. Delirium is a less dramatic
form of neurologic injury but, when sought, is strikingly prevalent. In
addition, delirium in the intensive care unit is associated with
increased mortality and poorer functional recovery, prompting
investigation into preventative and therapeutic strategies to
counter delirium. Finally, neurologic damage may persist long after
the patient’s recovery from critical illness, as is the case for
cognitive dysfunction detected months and years after critical
illness. Psychiatric impairment including depression or post-
traumatic stress disorder may also arise. Mechanisms contributing
to each of these entities are reviewed.
Introduction
Among the most difficult things we do as critical care
physicians is attempt to predict for a patient or their family the
outcome of critical illness. For many individuals, the most
pressing question becomes ’Will I (or my loved one) return to
my (their) present level of functioning, or will there be a
persistent disability?’ The answer to this question can be
obscure for any patient with critical illness, but prognosti-
cation becomes of paramount importance for those in whom
issues of neurological injury arise, especially considering
89% of Americans surveyed would not wish to be kept alive if
they sustained severe cognitive impairment [1]. This review is
intended to highlight recent advances in our understanding
and recognition of brain dysfunction – its pathophysiology,
significance, and outcomes – from the acute setting to the
months following critical illness.
Coma
When a patient fails to respond to his or her environment with
any verbal, motor, or psychological interaction, we refer to the
patient as comatose. Coma is a common occurrence in the
intensive care unit (ICU). It was the primary reason for
intubation in approximately 17% of patients in a large inter-
national trial evaluating the characteristics of patients receiving
mechanical ventilation, occurring more frequently than con-
gestive heart failure, trauma, or pneumonia as an indication to
intubate [2]. For comatose patients, the outcome may vary
from death or a persistent vegetative state, to various
degrees of cerebral disability, or, in the best case, to full
neurologic recovery. Because patients’ reported preference
for ongoing medical care is largely determined by the
perceived outcome of each intervention [1], there exists a
clear imperative to improve prognostication in coma.
Following drug overdose and trauma, the most common
cause of coma in the United States is cardiac arrest [3,4].
Eighty percent of survivors of cardiac arrest will be comatose
following resuscitation [5]. Unfortunately, long-term survival
rates of cardiopulmonary resuscitation (CPR) remain poor;
approximately 29% of patients who suffer out-of-hospital
cardiac arrest are alive at 4 hours but fewer than 10% survive
to hospital discharge [6,7], while 18% of adults who suffer
inhospital cardiac arrest survive to hospital discharge [8].
Because the outcome of cardiac arrest can vary so
dramatically – from death or permanent disability to a
meaningful, functional recovery – much recent research has
focused upon predicting which initial survivors of CPR will go
on to enjoy a long-term recovery. Much of this research has
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now been extended to the comatose critically ill population at
large, which is then of tremendous use to clinicians in the
ICU.
Prognosis in coma
Clinical examination
Classically, the main determinant used by clinicians to
prognosticate for patients with brain dysfunction has been
the clinical neurological examination. In addition to documen-
ting the patient’s Glasgow Coma Scale (GCS) [9], the
recommended clinical assessment of the comatose patient
involves assessment of brainstem reflexes (pupillary, corneal,
gag/cough) and vestibular reflexes (oculomotor or ‘Doll’s eye’
and cold caloric testing), as well as assessing for seizure or
myoclonic activity.
In their landmark paper describing the utility of the clinical
examination in anoxic coma, Levy and colleagues attempt to
simplify the pertinent examination. They report that, out of
210 patients, none who had absent corneal or pupillary
reflexes at 24 hours or absent motor response at 72 hours
ever regained an independent lifestyle [10].
A recent meta-analysis of 11 studies of the clinical exami-
nation in comatose patients following cardiac arrest found
that various examiners – nurses, residents, and attending
physicians – are moderately to substantially in agreement
about components of the GCS and brainstem reflexes, with
only one study showing diminished precision among less
experienced observers [5,11]. The meta-analysis also
examined the accuracy of various aspects of the clinical
examination performed at differing time points for predicting
outcome of post-arrest coma. With a pooled sample size of
over 1,900 patients, the proportion of patients dying or
having a poor neurologic outcome – severe cerebral
disability, coma, or persistent vegetative state – was 77% [5].
At 24 hours, the clinical findings with the highest likelihood
values to predict poor outcome were absent pupil response
or absent corneal response, with each result indicating that
poor outcome was 10 times more likely. At 72 hours post
arrest, only an absent motor response accurately predicted
death or poor outcome. Both the GCS and the Innsbruck
Coma Scale, which combines brainstem reflexes and the
GCS, were less predictive than individual motor and
brainstem responses for bad outcome. Surprisingly, no
element of the clinical examination could accurately predict a
good neurologic outcome.
Electrophysiologic and serum markers
Given the imperfection of the clinical examination to guide
prognosis, attention has focused on other potential diag-
nostic methods. Electroencephalography (EEG) has been
extensively studied in comatose patients. If the EEG pattern is
isoelectric 72 hours after an ischemic event, the chance of
survival or even of recovery of consciousness is essentially
zero [10,12,13]. If a burst-suppression pattern is observed,
there is almost no chance of survival without severe
neurologic disability [12,13].
In the recent Prognosis in Post-Anoxic Coma (PROPAC)
study [13], EEG was one of the clinical variables examined
along with physical examination findings, biochemical
variables, and somatosensory evoked potentials (SSEP) to
predict outcome of 407 patients who were comatose
following CPR. EEG performed modestly well at predicting
poor outcome, meaning death or persistent unconsciousness
at 1 month. If the EEG had no activity greater than 20 µV at
72 hours post arrest, the positive likelihood ratio of a poor
outcome was 17, with no false positives. If the EEG showed
burst-suppression activity at 72 hours, the positive likelihood
ratio of a poor outcome was 5, with no false positives.
Conversely, the finding of status epilepticus by EEG at
72 hours did not increase the likelihood of a poor outcome,
with a likelihood ratio of 1. EEG performs less well than
SSEP at predicting poor outcome – the likelihood ratio for
absent N20 SSEP (see later) at 24 hours was 29, with no
false positives – yet a small number of patients with intact
SSEP (13%) did have poor prognosis confirmed by EEG
alone [13]. As such, EEG at 72 hours post anoxic event may
help to determine patients with a low likelihood of survival or
regaining consciousness.
Serum markers are another potential prognostic aid that have
recently garnered significant attention. Of the many proposed
markers, including myelin basic protein, von Willebrand factor
antigen, soluble intracellular adhesion molecule-1, neuron-
specific enolase (NSE), and S-100β, the latter two have
shown considerable promise.
S-100β is the β-subunit of a dimeric calcium-binding protein
which is highly brain specific. Serum levels appear to rise in
response to astrocyte damage, and circulating elevations
have been reported in patients with cerebral ischemia,
traumatic brain injury, postcoronary artery bypass cognitive
decline, and respiratory failure [14-18]. In addition, S-100β
levels are correlated with measures of head injury severity
and outcomes [19]. S-100β increases may be associated
with systemic inflammation, as the serum trajectory of this
protein seemed to mirror a similar increase in IL-8 levels in
patients who were 12 hours post cardiac arrest [20]. While
the levels of serum S-100β have been proposed as a marker
to help prognosticate the extent of brain damage in patients
suffering anoxic–ischemic coma, the PROPAC study was
unable to validate a cut-off value for this marker [13,21].
NSE is a superior biomarker for coma prognostication. NSE
may be envisioned as a marker of neuronal damage because
it is a protein-based enzyme found primarily within neurons.
Like S-100β, serum levels of NSE rise following traumatic
brain injury and correlate with outcome in severe head injury
[22-24]. Eighty-eight percent of cardiac arrest patients
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in NSE levels, and this decrease correlated with a better
neurologic outcome at 6 months [25]. In the same study,
serum S-100β failed to show a decrement with hypothermia.
Zandbergen and colleagues suggested a cut-off value of
NSE greater than 33 µg/l as indicative of poor neurologic
outcome following ischemic–anoxic insult, and this threshold
was validated by the PROPAC study [13,21]. When the NSE
level is above the threshold level at 24 hours post arrest, the
likelihood of a poor outcome increases 36-fold. No patient
with a serum NSE >33 µg/l had a good outcome [13].
Interestingly, results from NSE analysis and from SSEP
analysis appear to be complementary [13]. Unfortunately, the
potential utility of NSE is limited by its current availability. At
our institution, the serum test is a send-out laboratory test
with a 5-day turnover time, despite its relatively modest cost
($185).
Perhaps the most definitive test to determine poor outcome in
post-anoxic coma is the SSEP. Because evoked potential
waveforms are so integrally related to their corresponding
anatomic structures, absence of a specific evoked potential
can localize the conduction deficit to within a few centimeters
[26]. SSEP are ideal in that they are extremely resistant to
being altered by nonpathologic factors, and thus are
unaffected by general anesthesia or even barbiturate-induced
coma [27,28]. If the N20 signal – triggered by stimulating a
median nerve, with expected waveforms then generated in
the brachial plexus, upper cervical cord, thalamic nuclei, and
primary sensory cortex – is bilaterally absent in a comatose
patient, the patient’s outcome at best will be a persistent
vegetative state [29,30].
In a meta-analysis of SSEP compared with other methods of
neurologic testing, SSEP were found superior to pupil exami-
nation, to motor response, to EEG, to computed tomography,
and to the GCS in predicting a negative outcome, with the
specificity and the negative predictive value essentially 100%
[31]. In another study, despite receiving long-term intensive
care treatment, all 86 patients with bilateral loss of N20
SSEP within 7 days of the onset of coma proceeded to die
without awakening from coma [32]. Likewise, the PROPAC
study found that, even when measured just 24 hours after the
onset of coma from anoxic–ischemic arrest, N20 SSEP that
were bilaterally absent invariably predicted either death or a
poor neurological outcome [13].
As mentioned previously, the results of SSEP do not
completely overlap with NSE or with tests such as EEG.
Because both the NSE and SSEP tests are highly specific
but are not very sensitive, the PROPAC group tested them in
combination to increase the diagnostic yield. The combi-
nation of either NSE >33 µg/l or bilaterally absent N20
SSEP identified 66% of comatose patients with a poor
prognosis. The addition of EEG at 72 hours, when it revealed
either an isoelectric low voltage or a burst-suppression
pattern, allowed the identification of an additional small
number of patients with poor outcome. In all, 356 of 407
comatose patients (87%) died or remained unconscious at
1 month; the combination of SSEP, NSE, and EEG permitted
prediction of this poor outcome for the vast majority (252 of
356, 71%) of these patients within 3 days of their CPR event
[13]. Table 1 describes the predictive ability of the most helpful
tools to determine poor outcome for comatose patients.
Treatment of coma
Recognizing that the probability of poor neurologic outcome
following cardiac arrest remains disappointingly high at
approximately 77% [5], much interest has been generated by
recent trials demonstrating that therapeutic hypothermia can
reduce mortality and can improve neurologic outcome.
In a European study of patients following ventricular fibrilla-
tion arrest, 275 subjects were randomized either to standard
care with normothermia or to therapeutic hypothermia of
32–34°C for 24 hours [33]. Cooling was achieved with an
external cooling device over approximately 8 hours. The
neurologic outcome at 6 months was favorable (good recovery
or moderate cerebral disability) rather than poor (severe
cerebral disability, persistent vegetative state, or death) in
55% of cooled patients compared with 39% of controls
(P = 0.009) [33]. The mortality at 6 months was also
significantly reduced in the hypothermia group (from 55% to
41%, P = 0.02), and no excess complications were noted in
the treatment group [33].
A similar study in Australia applied external cooling for
12 hours to patients who were comatose following CPR for
ventricular fibrillation, and likewise found an improvement in
outcome as judged by discharge status to home or to a
rehabilitation facility, rather than death or discharge to a long-
term nursing facility [34]. The Australian study failed to detect
a mortality difference between groups. Both clinical trials
sedated all patients during the cooling and rewarming period,
a mandatory corollary if neuromuscular blockade is used to
prevent shivering.
Delirium
While coma is undoubtedly the most dramatic form of brain
dysfunction faced in the ICU, it is not the most common.
Delirium – defined as an acute, fluctuating change in mental
status, with inattention and an altered level of consciousness –
occurs in the majority of patients in the ICU. Inattentiveness
and a fluctuating level of arousal distinguish delirium from
acute anxiety [35], whereas agitation is best described as
‘the motor restlessness that accompanies anxiety’ [36].
Delirium has been detected in 70–80% of mechanically
ventilated patients in the ICU, and in approximately 70% of all
ICU patients aged 65 years or older [37-39]. Younger
patients have a decreased risk compared with their elders,
Available online http://ccforum.com/content/10/4/223but studies nevertheless find that 57% of patients under age
65 become delirious in the ICU [40].
Each of these studies detected delirium using the Confusion
Assessment Method for the ICU (CAM-ICU), an instrument
adapted for use in nonverbal patients and validated for its
specificity and reliability in determining delirium [37]. Prior to
the development of the CAM-ICU, studies regarding brain
dysfunction of critically ill patients were hampered by
imprecise definitions of delirium, or by reliance upon verbal
patients and special psychiatric training for the health care
providers involved. The CAM-ICU consists of four features,
each with a dichotomous, absent versus present designation.
Echoing the accepted definition of delirium, a positive score
indicates the presence of acute onset with fluctuating course
and inattentiveness, as well as either disorganized thinking or
an altered level of consciousness [37].
Many different manifestations of delirium are demonstrated by
delirious patients. While hyperactive delirium with extensive
motor restlessness is easily recognized by caretakers, many
critically ill patients will actually manifest lethargy, withdrawal,
and psychomotor slowing. This latter form, often referred to
as hypoactive or ‘quiet’ delirium, is frequently unrecognized
precisely because the patient is outwardly calm and peaceful.
When over 600 consecutive ICU patients were studied for
delirium, a mixed-type delirium – involving periods of hypo-
activity and withdrawal and occasional periods of restless-
ness – was found to be the most common motoric subtype
[40]. Pure hyperactive delirium was quite uncommon, occur-
ring in fewer than 2% of patients, and exclusively in patients
younger than 65 years of age. Strictly hypoactive delirium
occurred in 45% of patients, and was the most frequent type
of delirium observed in elderly patients [40].
Risk factors
Along with age, a number of other risk factors for the
development of delirium have been identified. Mechanical
ventilation increases the risk approximately threefold, whereas
increasing severity of illness, as determined by the Acute
Physiology and Chronic Health Evaluation II score, has a
small but significant association with delirium [40]. In the
critically ill elderly, the presence of dementia was associated
with a 40% increase in delirium (relative risk, 1.4) [39].
A potential risk factor that has received little attention to date
is race. A recent study found that Black patients had a
significantly increased risk for developing hypoactive delirium
as compared with Hispanic or White patients [40].
In hospitalized but non-ICU patients, other identified risk
factors include visual impairment, hearing impairment, sleep
deprivation, immobility, concurrent illness, and polypharmacy
[41]. The link between medication and delirium is not wholly
understood. Long believed to be the leading iatrogenic cause
of delirium, psychoactive medications including analgesics
and sedatives have been associated with a higher rate of
delirium in some, but not all, studies of critically ill patients
[42,43]. Benzodiazepines appear to pose a particular hazard
in this regard [43,44].
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Table 1
Prognosis of a comatose patient
Primary assessment
Glasgow Coma Scale <8? Patient is comatose
No response to environment?
At 24 hours
Clinical examination
Absent pupillary response? Probability of a poor outcome, 97%
Absent motor response? Probability of a poor outcome, 97%
Somatosensory evoked potentials, absent N20 signal bilaterally Probability of a poor outcome, 100%
Serum neuron-specific enolase ≥33 µg/l Probability of a poor outcome, 100%
At 72 hours
Clinical examination
Absent motor response? Probability of a poor outcome, 97%
Somatosensory evoked potentials, absent N20 signal bilaterally Probability of a poor outcome, 100%
Serum neuron-specific enolase ≥33 µg/l Probability of a poor outcome, 100%
Electroencephalography, isoelectric or burst-suppression Probability of a poor outcome, 100%
‘Poor outcome’ is defined as death or persistent coma 1 month later [5,13].Associated mortality
While delirium in the ICU remains disappointingly common,
we are only beginning to appreciate its deeper significance.
Just as we recognize septic shock or acute respiratory distress
syndrome (ARDS) as indicators of critical organ dysfunction
of the cardiopulmonary systems, delirium may be thought of
as a marker of acute central nervous system dysfunction.
Lending credence to this argument is the fact that delirium,
as measured by the CAM-ICU, is an independent risk factor
for mortality in ventilated ICU patients [38,45].
A study of 275 ventilated patients found that delirious
patients had more than twice the 6-month mortality rate of
nondelirious patients [38]. Delirium was also associated with
a longer hospital stay and with a higher rate of cognitive
impairment at discharge [38]. In older patients, almost one-
half of the patients demonstrating delirium in the ICU
continued to be delirious during the post-ICU period, and
persistent delirium has been associated with a poor
functional recovery following acute illness [39,46].
Potential mechanisms
In evaluating the possible mechanisms underlying delirium,
much interest has centered on the brain’s response to injury
and its subsequent inflammatory response (Figure 1). Early
research focused on ischemic brain injury. More recently,
attention has shifted to an inflammation hypothesis of
delirium. When confronted with systemic infections, the
central nervous system evokes a cytokine cascade that can
induce cell infiltration and tissue damage, which could in
turn affect neuronal activity, resulting in delirium [18,47-49].
A study of patients undergoing surgery for hip fracture
lends credence to the theory that inflammation drives brain
injury; complications including postoperative delirium were
significantly associated with higher levels of C-reactive
protein, an acute-phase reactant stimulated by acute inflam-
mation [50].
Another active area of interest concerns dysregulation of
neurotransmitter systems, including acetylcholine, γ-amino-
butyric acid (GABA), dopamine, serotonin, and norepineph-
rine. Drugs with anticholinergic properties have long been
known to precipitate cognitive dysfunction. Even more intri-
guing, acetylcholine activates pathways that have been shown
to inhibit proinflammatory cytokine synthesis and to protect
against both ischemia-reperfusion injury and endotoxemia,
suggesting that deficits in acetylcholine may trigger a neuro-
inflammatory response [51]. GABA activity, which typically
depresses neuronal excitability, is implicated in hepatic
encephalopathy and alcohol or benzodiazepine withdrawal
[18]. Benzodiazepines and most other sedative hypnotics act
via GABA-receptor stimulation, and many of them impair
cognitive function at least acutely. Dopamine, which tends to
have excitatory effects, has been implicated as a risk factor for
delirium when given exogenously, and endogenous dopa-
minergic hyperfunction via upregulated dopamine receptors is
thought to underlie schizophrenia and to possibly contribute to
the development of delirium [52].
Prevention and treatment of delirium
Most research on the prevention of delirium to date has
focused on hospitalized but not critically ill patients. The Yale
Delirium Prevention Trial used a targeted intervention to
minimize six risk factors common to hospitalized patients, by
providing orientation activities, early mobilization, efforts to
prevent sleep deprivation and to avoid the use of psycho-
active medications, and use of hearing aids and eyeglasses
to improve communication [53]. By applying this intervention,
delirium was reduced from 15% in controls to 9.9% in the
study group [53]. Unfortunately, at 6 months there was no
sustained improvement in cognitive or functional outcomes
for the study group [41].
In critically ill patients, only one small preliminary trial on the
prevention of delirium has been published in abstract form.
Forty-two patients undergoing elective cardiac surgery were
randomized to postoperative sedation with dexmedetomidine,
propofol, or midazolam at the time of sternal closure. In the
dexmedetomidine group 8% of patients developed delirium,
compared with 50% in those patients sedated with either
propofol or midazolam [54]. This difference was not
statistically significant given the small number of patients, but
the finding is intriguing since dexmedetomidine, an α-agonist,
is thought to spare the GABA-receptor pathway, and may
potentiate endogenous sleep-promoting pathways [55].
Treatment of delirium in the ICU is a largely unstudied
territory. Just as in non-ICU patients, once delirium is identi-
fied in ICU patients, management should focus upon
identifying potential precipitating factors, providing supportive
Available online http://ccforum.com/content/10/4/223
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Figure 1
Potential mechanisms contributing to intensive care unit-associated
delirium [18,49,56]. ACh, acetylcholine; GABA, γ-aminobutyric acid;
5HT, serotonin.
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↑ Dopaminecare, and preventing further complications [56]. Once life-
threatening complications such as hypoxemia, hypoperfusion,
metabolic derangements, severe pain, and infection have
been excluded, attention should turn to the patient’s
medications and environment in an attempt to minimize any
factor that might exacerbate delirium. Reorientation,
mobilization, provision of family support and of hearing or
visual aids, attention to the patient’s comfort, including proper
positioning and removal of unnecessary catheters, and
attempts to encourage a normal sleep–wake cycle may all
help to attenuate cognitive impairment.
Small studies report the improvement of sleep among
critically ill patients who were randomized to receive a
6-minute back massage or to receive therapeutic touch by a
specially trained nurse [57,58]. A study in patients
recovering from orthopedic surgery found decreased
delirium and faster readiness to ambulate for patients
randomized to receive music therapy in their recovery room
[59]. Such alternative therapies, although untested, may
have a role in treating delirium once it arises. Pharmacologic
therapies to treat the symptoms of delirium should be
reserved for patients demonstrating agitation with risk for
self-harm, including pulling at catheters or endotracheal
tubes, and should occur only after nonpharmacologic treat-
ment has been initiated.
The US Food and Drug Administration has not currently
approved any medication for the treatment of delirium. If
medication is to be used, choices include antipsychotics
such as haloperidol or resperidone, benzodiazepines, or
antidepressants with hypnotic effects. A recent retrospective
study suggests that the use of haloperidol in mechanically
ventilated patients is associated with reduced hospital
mortality, but delirium was not assessed as part of the study
[60]. Postulated mechanisms for the observed decrease in
mortality include hypotheses that haloperidol may decrease
the administration of sedative medication, or that it may
potentiate central-nervous-system-mediated anti-inflammatory
pathways, including the direct inhibition of certain pro-
inflammatory cytokines by haloperidol [60,61]. While some
guidelines suggest haloperidol as the treatment of choice for
ICU delirium [35], its side effects may include extrapyramidal
effects, acute dystonias, malignant hyperthermia, hypo-
tension, and, most worryingly, prolonged QT syndrome
leading to torsade de pointes [62].
Atypical antipsychotics such as olanzapine or resperidone
may have a decreased incidence of side effects, but the risk
profile remains unchanged and there is little published
experience using these medications in critically ill patients
[63].
Benzodiazepines are generally to be avoided in the delirious
patient, as their use has been associated with increased rates
of delirium and paradoxical excitation or agitation.
Residual neuropsychiatric effects of critical
illness: cognitive dysfunction and
post-traumatic stress disorder
To survive critical illness in the modern ICU, where up to one-
third of patients may succumb to their disease, is a justifiable
cause for happiness. As mortality from ARDS, renal failure,
and other disorders decreases, however, the logical corollary
is that more patients are living to experience potential long-
term complications of critical illness [64-66]. Increasingly,
practitioners are recognizing that a significant proportion of
survivors of critical illness will be affected by neuropsycho-
logical complications, which can impair their health status
and functional outcome, cognitive abilities, or emotional and
psychological health.
Critically ill patients frequently manifest cognitive impairment.
One study of ICU patients aged 65 years or older found that
30–40% of patients screened positive for pre-existing
dementia at the time of hospitalization [67]. At hospital
discharge, 50% of another prospectively studied group of
mechanically ventilated ICU patients had detectable neuro-
psychologic abnormalities, and one-third of the total group
remained cognitively impaired 6 months later [68]. Neuro-
cognitive dysfunction appears to improve with time, although
not to normalize. A study of mixed medical and surgical ICU
patients found that 35% of survivors of critical illness
manifested profound cognitive impairment at 3 months,
whereas only 4% were severely impaired at 9 months [69].
The neuropsychiatric dysfunction of some patients takes the
form of post-traumatic stress disorder (PTSD), characterized
by the development and persistence of intrusive recollec-
tions, avoidance symptoms, and hypervigilance 1–3 months
after a traumatic event. In addition to the strain the disorder
itself places upon social functioning and psychological health,
PTSD is implicated in increased rates of depression,
substance abuse, and suicide attempts [70,71].
Among survivors of ARDS, one study reported that over 27%
of patients self-reported symptoms that would characterize
them as having PTSD [72]. This was a strikingly higher
proportion of PTSD-affected individuals than was found in
groups of patients who had undergone disfiguring maxillo-
facial surgery or in groups of soldiers who had spent con-
siderable time peace-keeping in Cambodia [72]. In addition,
patients who reported memory of more than one traumatic
experience from the ICU were far more likely to report symp-
toms of PTSD, suggesting that the number of adverse recollec-
tions might predispose patients to developing PTSD [72].
To further study this issue, a group prospectively examined
the relationship between memory, delusions, and PTSD with
standardized interviews 2 weeks following patients’ critical
illness, and again 8 weeks later. Distinguishing factual
memories from delusional ones, the development of PTSD
symptoms were predicted only by the presence of delusional
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presence of factual memories – despite being memories of
unpleasant events – seemed protective against subsequent
PTSD symptoms [73]. A similar study found that patients who
reported PTSD-related symptoms 3 months after their critical
illness recalled fewer factual memories of their ICU stay
immediately after ICU discharge [74].
Interestingly, patients are not alone in their risk of developing
PTSD. Several studies have found high rates of PTSD
symptoms in family members of ICU patients, especially
those related to patients who had unfavorable outcomes from
their illness and those who participated in end-of-life
decision-making for their loved one [75,76]. Depression may
also be more common in survivors of critical illness. While a
detailed overview of the literature supporting this assertion is
beyond the scope of this paper, the reader is directed to an
excellent review recently published by Weinert [77].
The mechanisms by which critical illness-associated neuro-
psychiatric dysfunction occur are not precisely understood.
Multiple factors undoubtedly contribute, some of which are
well documented. Hypoxemia has been associated with
cognitive decline in populations with ARDS and chronic
obstructive pulmonary disease, with longer amounts of time
spent hypoxic correlating with deficits in memory, attention,
speed of processing, visuo-spatial skills, and executive function
[78,79]. At 1 year, 30% of one cohort of ARDS survivors
demonstrated global cognitive decline and 78% demon-
strated impairment in at least one cognitive domain [78].
Delirium may be another potentiator of neuropsychological
injury. In addition to increased mortality rates, patients suffer-
ing delirium during the ICU stay were nine times more likely to
demonstrate cognitive impairment on hospital discharge
compared with nondelirious patients [38]. The only study to
examine the link between delirium and long-term neuro-
cognitive dysfunction in critically ill patients was under-
powered to find a significant relationship, but it did find a
trend toward increased duration of delirium in cognitively
impaired patients [68]. Nonetheless, delirium is not necessary
for the development of cognitive dysfunction; one study found
that between 30% and 50% of nondelirious patients demon-
strated memory and problem-solving deficits 2 months after
their critical illness [80].
Medication, particularly sedatives and psychoactive agents,
administered during and after critical illness may also play a
role. In mechanically ventilated patients who were randomized
to either routine sedation or a daily sedative interruption,
patients receiving daily sedative interruption demonstrated
trends toward a lower incidence of PTSD and toward a better
psychosocial adjustment to illness [81]. In addition to
receiving smaller daily and total amounts of sedatives, the
group receiving sedative interruption also had 2 days fewer
on the ventilator and 3 days fewer in the ICU than the control
group [82]. The beneficial effect of sedative interruption on
psychological well-being might be ascribed to a decreased
medication amount, to a decreased time on the ventilator, or
to different memory processing among the intervention group,
highlighting the complexity of potential contributing factors.
Patient factors – including advancing age, declining
educational level, or coexisting depression or anxiety – may
each pose additive risks for the development of cognitive
decline following critical illness.
We are only beginning to comprehend the scope of
neurocognitive sequelae following critical illness. To date,
research has focused on identifying the different forms of
neurocognitive impairment and establishing each form's
prevalence and risk factors. As such, we do not yet know how
best to prevent or treat ICU-related cognitive impairment. For
some aspects of the problem, significant inroads have been
made. For example, studies of patients at risk for PTSD
following trauma or burns have led to a number of potential
preventative measures, including adequate pain control with
morphine and empiric use of propranolol following trauma
[83,84]. In addition, given the evidence that acquisition of
factual memories in the ICU is protective against the
development of PTSD, we advocate daily interruption of
sedatives for all ventilated patients in the ICU, to allow daily
neurologic assessment and daily readjustment of sedative to
the patient’s needs [82]. Once PTSD has developed,
cognitive behavioral therapy is generally the mainstay of
therapy, but this may be supplemented by use of selective
serotonin receptor inhibitors [85].
Perhaps most importantly we are learning that it is only by
recognition of our patients’ vulnerability to neurocognitive
impairment that we may appropriately screen and diagnose
them. When we have the opportunity to follow patients out of
the ICU, we must actively investigate their cognitive,
emotional, and psychological state. Patients and family
members should be warned about potential neurologic
outcomes, and should be reassured about the commonality
of their experiences. Because we may not care for our
patients once they have survived their critical illness, we must
share with our primary care colleagues our hopes and
concerns for patients’ psychological health, just as we do
regarding their physical health. By bridging our care with this
crucial follow-up, we are likely to improve our patients’
longitudinal outcomes.
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